Cargando…

The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma

BACKGROUND: To explore the metabolic differences of follicular thyroid carcinoma (FTC) by metabonomics, to find potential biomarkers for the diagnosis of FTC, and to explore the pathogenesis and diagnosis and treatment strategies of FTC. METHOD: The metabonomics of 15 patients with FTC and 15 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jiali, Yang, Yang, Du, Wei, Li, Gang, Wu, Yao, Luo, Ruihua, Liu, Shanting, Fan, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814718/
https://www.ncbi.nlm.nih.gov/pubmed/36620583
http://dx.doi.org/10.3389/fonc.2022.1076548
_version_ 1784864198598066176
author Qin, Jiali
Yang, Yang
Du, Wei
Li, Gang
Wu, Yao
Luo, Ruihua
Liu, Shanting
Fan, Jie
author_facet Qin, Jiali
Yang, Yang
Du, Wei
Li, Gang
Wu, Yao
Luo, Ruihua
Liu, Shanting
Fan, Jie
author_sort Qin, Jiali
collection PubMed
description BACKGROUND: To explore the metabolic differences of follicular thyroid carcinoma (FTC) by metabonomics, to find potential biomarkers for the diagnosis of FTC, and to explore the pathogenesis and diagnosis and treatment strategies of FTC. METHOD: The metabonomics of 15 patients with FTC and 15 patients with follicular thyroid nodules(FTN) treated in Henan Cancer Hospital were analyzed by liquid chromatography-mass spectrometry (LC-MS). RESULTS: The analysis showed that the metabolite profiles of FTC tissues could be well distinguished from those of control tissues, and 6 kinds of lipids were identified respectively, including lysophosphatidic acid(LysoPA) [LysoPA(0:0/18:0),LysoPA(0:0/18:2(9Z,12Z)],LysoPA[20:4(8Z,11Z,14Z,17Z)/0:0)]; phosphatidic acid(PA) [PA(20:3(8Z,11Z,14Z)/0:0),PA(20:4(5Z,8Z,11Z,14Z)/0:0),PA(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)]; lysophosphatidylcholine(LPC) [LPC(18:1),LPC(16:0),LPC[16:1(9Z)/0:0],LPC(17:0),LPC[22:4(7Z,10Z,13Z,16Z),LPC(20:2(11Z,14Z); phosphatidylcholine(PC)(PC(14:0/0:0),PC(16:0/0:0); sphingomyelin(SM) (d18:0/12:0); fatty acid(FA)(18:1(OH3)]. There are 2 kinds of amino acids, including L-glutamate,L-glutamine.There are 3 other metabolites, including retinol,flavin adenine dinucleotide,androsterone glucuronide.Lipid metabolites are the main metabolites in these metabolites.The metabolic pathways related to FTC were analyzed by KEGG and HMDB, and 9 metabolic pathways were found, including 4 amino acid related metabolic pathways, 1 lipid metabolic pathways and 4 other related pathways. CONCLUSION: There are significant differences in many metabonomic characteristics between FTC and FTN, suggesting that these metabolites can be used as potential biomarkers. Further study found that LysoPA and its analogues can be used as biomarkers in the early diagnosis of FTC.It may be related to the abnormal metabolism of phospholipase D (PLD), the key enzyme of LysoPA synthesis caused by RAS pathway. At the same time, it was found that the metabolic pathway of amino acids and lipids was the main metabolic pathway of FTC. The abnormality of LysoPA may be the cause of follicular tumor carcinogenesis caused by lipid metabolic pathway.
format Online
Article
Text
id pubmed-9814718
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98147182023-01-06 The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma Qin, Jiali Yang, Yang Du, Wei Li, Gang Wu, Yao Luo, Ruihua Liu, Shanting Fan, Jie Front Oncol Oncology BACKGROUND: To explore the metabolic differences of follicular thyroid carcinoma (FTC) by metabonomics, to find potential biomarkers for the diagnosis of FTC, and to explore the pathogenesis and diagnosis and treatment strategies of FTC. METHOD: The metabonomics of 15 patients with FTC and 15 patients with follicular thyroid nodules(FTN) treated in Henan Cancer Hospital were analyzed by liquid chromatography-mass spectrometry (LC-MS). RESULTS: The analysis showed that the metabolite profiles of FTC tissues could be well distinguished from those of control tissues, and 6 kinds of lipids were identified respectively, including lysophosphatidic acid(LysoPA) [LysoPA(0:0/18:0),LysoPA(0:0/18:2(9Z,12Z)],LysoPA[20:4(8Z,11Z,14Z,17Z)/0:0)]; phosphatidic acid(PA) [PA(20:3(8Z,11Z,14Z)/0:0),PA(20:4(5Z,8Z,11Z,14Z)/0:0),PA(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)]; lysophosphatidylcholine(LPC) [LPC(18:1),LPC(16:0),LPC[16:1(9Z)/0:0],LPC(17:0),LPC[22:4(7Z,10Z,13Z,16Z),LPC(20:2(11Z,14Z); phosphatidylcholine(PC)(PC(14:0/0:0),PC(16:0/0:0); sphingomyelin(SM) (d18:0/12:0); fatty acid(FA)(18:1(OH3)]. There are 2 kinds of amino acids, including L-glutamate,L-glutamine.There are 3 other metabolites, including retinol,flavin adenine dinucleotide,androsterone glucuronide.Lipid metabolites are the main metabolites in these metabolites.The metabolic pathways related to FTC were analyzed by KEGG and HMDB, and 9 metabolic pathways were found, including 4 amino acid related metabolic pathways, 1 lipid metabolic pathways and 4 other related pathways. CONCLUSION: There are significant differences in many metabonomic characteristics between FTC and FTN, suggesting that these metabolites can be used as potential biomarkers. Further study found that LysoPA and its analogues can be used as biomarkers in the early diagnosis of FTC.It may be related to the abnormal metabolism of phospholipase D (PLD), the key enzyme of LysoPA synthesis caused by RAS pathway. At the same time, it was found that the metabolic pathway of amino acids and lipids was the main metabolic pathway of FTC. The abnormality of LysoPA may be the cause of follicular tumor carcinogenesis caused by lipid metabolic pathway. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9814718/ /pubmed/36620583 http://dx.doi.org/10.3389/fonc.2022.1076548 Text en Copyright © 2022 Qin, Yang, Du, Li, Wu, Luo, Liu and Fan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qin, Jiali
Yang, Yang
Du, Wei
Li, Gang
Wu, Yao
Luo, Ruihua
Liu, Shanting
Fan, Jie
The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
title The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
title_full The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
title_fullStr The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
title_full_unstemmed The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
title_short The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
title_sort potential value of lc-ms non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814718/
https://www.ncbi.nlm.nih.gov/pubmed/36620583
http://dx.doi.org/10.3389/fonc.2022.1076548
work_keys_str_mv AT qinjiali thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT yangyang thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT duwei thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT ligang thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT wuyao thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT luoruihua thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT liushanting thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT fanjie thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT qinjiali potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT yangyang potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT duwei potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT ligang potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT wuyao potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT luoruihua potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT liushanting potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma
AT fanjie potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma